- Home
- MLNK vs NRIX Comparison
MLNK vs NRIX Comparison
Compare MLNK & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLNK
- NRIX
- Stock Information
- Founded
- MLNK 1998
- NRIX 2009
- Country
- MLNK United States
- NRIX United States
- Employees
- MLNK N/A
- NRIX N/A
- Industry
- MLNK Computer Software: Prepackaged Software
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- MLNK Technology
- NRIX Health Care
- Exchange
- MLNK Nasdaq
- NRIX Nasdaq
- Market Cap
- MLNK 1.5B
- NRIX 1.4B
- IPO Year
- MLNK 2021
- NRIX 2020
- Fundamental
- Price
- MLNK $19.64
- NRIX $19.14
- Analyst Decision
- MLNK Hold
- NRIX Strong Buy
- Analyst Count
- MLNK 6
- NRIX 17
- Target Price
- MLNK $23.50
- NRIX $30.29
- AVG Volume (30 Days)
- MLNK 278.1K
- NRIX 832.5K
- Earning Date
- MLNK 03-04-2025
- NRIX 02-13-2025
- Dividend Yield
- MLNK N/A
- NRIX N/A
- EPS Growth
- MLNK N/A
- NRIX N/A
- EPS
- MLNK N/A
- NRIX N/A
- Revenue
- MLNK $311,440,000.00
- NRIX $56,424,000.00
- Revenue This Year
- MLNK $5.98
- NRIX N/A
- Revenue Next Year
- MLNK $7.31
- NRIX $3.79
- P/E Ratio
- MLNK N/A
- NRIX N/A
- Revenue Growth
- MLNK 3.96
- NRIX N/A
- 52 Week Low
- MLNK $16.49
- NRIX $7.65
- 52 Week High
- MLNK $25.33
- NRIX $29.56
- Technical
- Relative Strength Index (RSI)
- MLNK 37.15
- NRIX 45.09
- Support Level
- MLNK $18.47
- NRIX $17.50
- Resistance Level
- MLNK $20.96
- NRIX $20.50
- Average True Range (ATR)
- MLNK 0.46
- NRIX 1.12
- MACD
- MLNK -0.03
- NRIX 0.16
- Stochastic Oscillator
- MLNK 39.97
- NRIX 54.67
About MLNK MeridianLink Inc.
MeridianLink Inc is a cloud-based software solution for financial institutions, including banks, credit unions, mortgage lenders, specialty lending providers, and consumer reporting agencies. It generates maximum revenue from Lending Software Solutions.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.